Pharmaceuticals company Torrent Pharmaceuticals announced Q3FY25 results Revenue at Rs 2,809 crore grew by 3% Gross Margin: 76.0%, Op. EBITDA margin at 32.5%. Op. EBITDA at Rs 914 crore, up by 5%. Net Profit after tax at Rs 503 crore, up by 14% No insulin CMO sales in the quarter. Dispatches restarted from January 2025. During the quarter, BRL depreciated by 17% YoY. Underlying revenue growth adjusted for above transient impact is 7% and Operating EBITDA growth is 12% Result PDF